| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
|
Medicine details |
|
| Medicine name | certolizumab pegol (Cimzia®) |
| Formulation | 200 mg solution for injection |
| Reference number | 79 |
| Indication | In combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDS) including methotrexate (MTX), has been inadequate. Certolizumab pegol can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. Certolizumab pegol has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX |
| Company | UCB Pharma Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/09/2009 |
| NICE guidance | |